Sarah E. Morris, PhD

How can we develop reliable predictive biomarkers for psychosis? And how can those biomarkers help us develop better treatments in the early stages of psychotic illness? The Accelerating Medicines Partnership in Schizophrenia is answering the call by bringing together experts in psychosis risk research from across the world in a 42-site international research network to focus on these developments.

Join Sarah E. Morris, PhD, of the National Institute of Mental Health and colleagues Scott Woods, MD, and Rene Kahn, MD, PhD, for “

The Accelerating Medicines Partnership in Schizophrenia: Big Data for Psychosis Prediction

American Psychiatric Association Annual Meeting

 on Saturday, May 21, 2022, at 10:30am. The presentation will feature an overview of the initiative; study protocol and methods; data infrastructure; and the ways the data collected will be made available to the scientific community.

Articles

The Accelerating Medicines Partnership in Schizophrenia aims to develop better treatments for the early stages of psychotic illness.